These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 20214604)

  • 1. Phage choice, isolation, and preparation for phage therapy.
    Gill JJ; Hyman P
    Curr Pharm Biotechnol; 2010 Jan; 11(1):2-14. PubMed ID: 20214604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing phage therapeutics.
    Goodridge LD
    Curr Pharm Biotechnol; 2010 Jan; 11(1):15-27. PubMed ID: 20214605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phage therapy in clinical practice: treatment of human infections.
    Kutter E; De Vos D; Gvasalia G; Alavidze Z; Gogokhia L; Kuhl S; Abedon ST
    Curr Pharm Biotechnol; 2010 Jan; 11(1):69-86. PubMed ID: 20214609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 'nuts and bolts' of phage therapy.
    Abedon ST
    Curr Pharm Biotechnol; 2010 Jan; 11(1):1. PubMed ID: 20214603
    [No Abstract]   [Full Text] [Related]  

  • 5. Phage therapy pharmacology.
    Abedon ST; Thomas-Abedon C
    Curr Pharm Biotechnol; 2010 Jan; 11(1):28-47. PubMed ID: 20214606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phage cocktails and the future of phage therapy.
    Chan BK; Abedon ST; Loc-Carrillo C
    Future Microbiol; 2013 Jun; 8(6):769-83. PubMed ID: 23701332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality and safety requirements for sustainable phage therapy products.
    Pirnay JP; Blasdel BG; Bretaudeau L; Buckling A; Chanishvili N; Clark JR; Corte-Real S; Debarbieux L; Dublanchet A; De Vos D; Gabard J; Garcia M; Goderdzishvili M; Górski A; Hardcastle J; Huys I; Kutter E; Lavigne R; Merabishvili M; Olchawa E; Parikka KJ; Patey O; Pouilot F; Resch G; Rohde C; Scheres J; Skurnik M; Vaneechoutte M; Van Parys L; Verbeken G; Zizi M; Van den Eede G
    Pharm Res; 2015 Jul; 32(7):2173-9. PubMed ID: 25585954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.
    Dąbrowska K; Abedon ST
    Microbiol Mol Biol Rev; 2019 Nov; 83(4):. PubMed ID: 31666296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hurdles in bacteriophage therapy: deconstructing the parameters.
    Tsonos J; Vandenheuvel D; Briers Y; De Greve H; Hernalsteens JP; Lavigne R
    Vet Microbiol; 2014 Jul; 171(3-4):460-9. PubMed ID: 24315040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations.
    Hagens S; Loessner MJ
    Curr Pharm Biotechnol; 2010 Jan; 11(1):58-68. PubMed ID: 20214608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phage therapy for plant disease control.
    Balogh B; Jones JB; Iriarte FB; Momol MT
    Curr Pharm Biotechnol; 2010 Jan; 11(1):48-57. PubMed ID: 20214607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteriophages: an appraisal of their role in the treatment of bacterial infections.
    Hanlon GW
    Int J Antimicrob Agents; 2007 Aug; 30(2):118-28. PubMed ID: 17566713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-evolutionary dynamics of the bacteria Vibrio sp. CV1 and phages V1G, V1P1, and V1P2: implications for phage therapy.
    Barbosa C; Venail P; Holguin AV; Vives MJ
    Microb Ecol; 2013 Nov; 66(4):897-905. PubMed ID: 24013213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteriophages and its applications: an overview.
    Sharma S; Chatterjee S; Datta S; Prasad R; Dubey D; Prasad RK; Vairale MG
    Folia Microbiol (Praha); 2017 Jan; 62(1):17-55. PubMed ID: 27718043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteriophages: an overview of the control strategies against multiple bacterial infections in different fields.
    Jamal M; Bukhari SMAUS; Andleeb S; Ali M; Raza S; Nawaz MA; Hussain T; Rahman SU; Shah SSA
    J Basic Microbiol; 2019 Feb; 59(2):123-133. PubMed ID: 30485461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational models of populations of bacteria and lytic phage.
    Krysiak-Baltyn K; Martin GJ; Stickland AD; Scales PJ; Gras SL
    Crit Rev Microbiol; 2016 Nov; 42(6):942-68. PubMed ID: 26828960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Possibilities of bacteriophage therapy].
    Skurnik M; Kiljunen S
    Duodecim; 2016; 132(8):712-9. PubMed ID: 27244930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriophage biocontrol in animals and meat products.
    Atterbury RJ
    Microb Biotechnol; 2009 Nov; 2(6):601-12. PubMed ID: 21255295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European regulatory aspects of phage therapy: magistral phage preparations.
    Verbeken G; Pirnay JP
    Curr Opin Virol; 2022 Feb; 52():24-29. PubMed ID: 34801778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.